- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04708418
Een studie waarin wordt geëvalueerd of pembrolizumab alleen of in combinatie met CMP-001 de werkzaamheid verbetert bij patiënten met een opereerbaar melanoom
Gerandomiseerde fase II-studie van neoadjuvant pembrolizumab alleen of in combinatie met CMP-001 bij patiënten met opereerbaar melanoom: onderzoek naar werkzaamheid en biomarkers
This phase II trial studies the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with melanoma that can be treated by surgery (operable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with CMP-001 may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. The addition of CMP-001 to pembrolizumab could improve the ability of the immune system to shrink tumors and to prevent them from returning.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
PRIMARY OBJECTIVE:
I. To evaluate the rate of pathologic complete response (pCR) rate in patients in each arm.
SECONDARY OBJECTIVES:
I. To evaluate the rate of pathologic near-complete/major response (pMR) of the neoadjuvant therapy in each arm.
II. To evaluate the pathologic response rate of un-injected lesions on the combination arm (Arm B).
III. To evaluate relapse-free survival (RFS) in each arm. IV. To evaluate overall survival (OS) in each arm. V. To evaluate the preoperative radiographic response rate in each arm. VI. To evaluate safety and toxicity of neoadjuvant therapy in each arm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A:
NEOADJUVANT PHASE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase.
ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo computed tomography (CT) or positron emission tomography (PET)/CT throughout the trial and may undergo optional biopsy at baseline and disease progression and optional collection of blood samples throughout the trial.
ARM B:
NEOADJUVANT PHASE: Patients receive VLP-encapsulated TLR9 agonist CMP-001 (CMP-001) subcutaneously (SC) on day 1 of cycle 1 and then intratumorally on days 8 and 15 of cycle 1, days 1, 8, and 15 of cycle 2, and day 1 of cycle 3. Patients also receive pembrolizumab IV over 30 minutes on day 8 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase.
ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo CT or PET/CT throughout the trial and may undergo optional biopsy at baseline and disease progression and optional collection of blood samples throughout the trial.
After completion of study treatment, patients are followed up at 30 days and then every 3 months if < 2 years from study entry, every 6 months if 2-5 years from study entry, and every 12 months if > 5 years from study entry for up to 10 years (15 years total follow up).
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Alaska
-
Anchorage, Alaska, Verenigde Staten, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Verenigde Staten, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Verenigde Staten, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Verenigde Staten, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Verenigde Staten, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Verenigde Staten, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Verenigde Staten, 99508
- Providence Alaska Medical Center
-
Fairbanks, Alaska, Verenigde Staten, 99701
- Fairbanks Memorial Hospital
-
-
Arizona
-
Tucson, Arizona, Verenigde Staten, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Verenigde Staten, 85719
- University of Arizona Cancer Center-North Campus
-
-
Arkansas
-
Fort Smith, Arkansas, Verenigde Staten, 72903
- Mercy Hospital Fort Smith
-
-
California
-
Burbank, California, Verenigde Staten, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Dublin, California, Verenigde Staten, 94568
- Epic Care-Dublin
-
Emeryville, California, Verenigde Staten, 94608
- Bay Area Breast Surgeons Inc
-
Emeryville, California, Verenigde Staten, 94608
- Epic Care Partners in Cancer Care
-
Martinez, California, Verenigde Staten, 94553-3156
- Contra Costa Regional Medical Center
-
Oakland, California, Verenigde Staten, 94609
- Alta Bates Summit Medical Center - Summit Campus
-
Oakland, California, Verenigde Staten, 94609
- Bay Area Tumor Institute
-
Orange, California, Verenigde Staten, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange, California, Verenigde Staten, 92868
- Saint Joseph Hospital - Orange
-
Walnut Creek, California, Verenigde Staten, 94597
- Epic Care Cyberknife Center
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, Verenigde Staten, 80012
- The Medical Center of Aurora
-
Boulder, Colorado, Verenigde Staten, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Centennial, Colorado, Verenigde Staten, 80112
- Rocky Mountain Cancer Centers - Centennial
-
Denver, Colorado, Verenigde Staten, 80218
- Presbyterian - Saint Lukes Medical Center - Health One
-
Denver, Colorado, Verenigde Staten, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Verenigde Staten, 80220
- Rocky Mountain Cancer Centers-Rose
-
Englewood, Colorado, Verenigde Staten, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Verenigde Staten, 80113
- Swedish Medical Center
-
Englewood, Colorado, Verenigde Staten, 80113
- Rocky Mountain Cancer Centers - Swedish
-
Englewood, Colorado, Verenigde Staten, 80113
- The Melanoma and Skin Cancer Institute
-
Greeley, Colorado, Verenigde Staten, 80631
- Banner North Colorado Medical Center
-
Littleton, Colorado, Verenigde Staten, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree, Colorado, Verenigde Staten, 80124
- Sky Ridge Medical Center
-
Lone Tree, Colorado, Verenigde Staten, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Loveland, Colorado, Verenigde Staten, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Thornton, Colorado, Verenigde Staten, 80260
- Rocky Mountain Cancer Centers-Thornton
-
-
Florida
-
Aventura, Florida, Verenigde Staten, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Verenigde Staten, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Verenigde Staten, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Verenigde Staten, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Plantation, Florida, Verenigde Staten, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, Verenigde Staten, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Verenigde Staten, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Verenigde Staten, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Verenigde Staten, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Verenigde Staten, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Verenigde Staten, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Verenigde Staten, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Verenigde Staten, 62902
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Verenigde Staten, 62918
- SIH Cancer Institute
-
Carthage, Illinois, Verenigde Staten, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Verenigde Staten, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Verenigde Staten, 60612
- University of Illinois
-
Decatur, Illinois, Verenigde Staten, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Verenigde Staten, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Verenigde Staten, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, Verenigde Staten, 62401
- Crossroads Cancer Center
-
Eureka, Illinois, Verenigde Staten, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Verenigde Staten, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Verenigde Staten, 61401
- Illinois CancerCare-Galesburg
-
Kewanee, Illinois, Verenigde Staten, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Verenigde Staten, 61455
- Illinois CancerCare-Macomb
-
Mount Vernon, Illinois, Verenigde Staten, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Verenigde Staten, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Verenigde Staten, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Verenigde Staten, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Verenigde Staten, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Verenigde Staten, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Verenigde Staten, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Verenigde Staten, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, Verenigde Staten, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Verenigde Staten, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Verenigde Staten, 62702
- Springfield Clinic
-
Springfield, Illinois, Verenigde Staten, 62781
- Springfield Memorial Hospital
-
Washington, Illinois, Verenigde Staten, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Richmond, Indiana, Verenigde Staten, 47374
- Reid Health
-
-
Iowa
-
Ames, Iowa, Verenigde Staten, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Verenigde Staten, 50010
- McFarland Clinic - Ames
-
Boone, Iowa, Verenigde Staten, 50036
- McFarland Clinic - Boone
-
Fort Dodge, Iowa, Verenigde Staten, 50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson, Iowa, Verenigde Staten, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Verenigde Staten, 50158
- McFarland Clinic - Marshalltown
-
-
Kansas
-
Garden City, Kansas, Verenigde Staten, 67846
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Verenigde Staten, 67530
- Central Care Cancer Center - Great Bend
-
-
Louisiana
-
Baton Rouge, Louisiana, Verenigde Staten, 70809
- Louisiana Hematology Oncology Associates LLC
-
Baton Rouge, Louisiana, Verenigde Staten, 70809
- Mary Bird Perkins Cancer Center
-
Houma, Louisiana, Verenigde Staten, 70360
- Terrebonne General Medical Center
-
-
Michigan
-
Battle Creek, Michigan, Verenigde Staten, 49017
- Bronson Battle Creek
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo, Michigan, Verenigde Staten, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Verenigde Staten, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Verenigde Staten, 49009
- Beacon Kalamazoo Cancer Center
-
Kalamazoo, Michigan, Verenigde Staten, 49048
- Beacon Kalamazoo
-
Muskegon, Michigan, Verenigde Staten, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Verenigde Staten, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Verenigde Staten, 49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Verenigde Staten, 49677
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, Verenigde Staten, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Verenigde Staten, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City, Michigan, Verenigde Staten, 49684
- Munson Medical Center
-
Wyoming, Michigan, Verenigde Staten, 49519
- University of Michigan Health - West
-
-
Missouri
-
Ballwin, Missouri, Verenigde Staten, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar, Missouri, Verenigde Staten, 65613
- Central Care Cancer Center - Bolivar
-
Cape Girardeau, Missouri, Verenigde Staten, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Verenigde Staten, 63703
- Mercy Cancer Center - Cape Girardeau
-
Farmington, Missouri, Verenigde Staten, 63640
- Parkland Health Center - Farmington
-
Jefferson City, Missouri, Verenigde Staten, 65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Verenigde Staten, 64804
- Freeman Health System
-
Joplin, Missouri, Verenigde Staten, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, Verenigde Staten, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Verenigde Staten, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Verenigde Staten, 64506
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Verenigde Staten, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Verenigde Staten, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Verenigde Staten, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Verenigde Staten, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Verenigde Staten, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Verenigde Staten, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Verenigde Staten, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Missoula, Montana, Verenigde Staten, 59802
- Saint Patrick Hospital - Community Hospital
-
-
Ohio
-
Beavercreek, Ohio, Verenigde Staten, 45431
- Indu and Raj Soin Medical Center
-
Centerville, Ohio, Verenigde Staten, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Verenigde Staten, 45459
- Dayton Physicians LLC-Miami Valley South
-
Cincinnati, Ohio, Verenigde Staten, 45236
- Oncology Hematology Care Inc-Kenwood
-
Dayton, Ohio, Verenigde Staten, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Verenigde Staten, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Verenigde Staten, 45415
- Dayton Physician LLC - Englewood
-
Findlay, Ohio, Verenigde Staten, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, Verenigde Staten, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, Verenigde Staten, 45840
- Orion Cancer Care
-
Franklin, Ohio, Verenigde Staten, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, Verenigde Staten, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Verenigde Staten, 45331
- Wayne Hospital
-
Greenville, Ohio, Verenigde Staten, 45331
- Dayton Physicians LLC-Wayne
-
Kettering, Ohio, Verenigde Staten, 45429
- Kettering Medical Center
-
Kettering, Ohio, Verenigde Staten, 45409
- Greater Dayton Cancer Center
-
Springfield, Ohio, Verenigde Staten, 45504
- Springfield Regional Cancer Center
-
Springfield, Ohio, Verenigde Staten, 45504
- Springfield Regional Medical Center
-
Troy, Ohio, Verenigde Staten, 45373
- Upper Valley Medical Center
-
Troy, Ohio, Verenigde Staten, 45373
- Dayton Physicians LLC - Troy
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Bend, Oregon, Verenigde Staten, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Verenigde Staten, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Verenigde Staten, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Verenigde Staten, 97420
- Bay Area Hospital
-
Newberg, Oregon, Verenigde Staten, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Verenigde Staten, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Verenigde Staten, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Verenigde Staten, 18104
- Saint Luke's Cancer Center - Allentown
-
Bethlehem, Pennsylvania, Verenigde Staten, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Easton, Pennsylvania, Verenigde Staten, 18045
- Saint Luke's Hospital-Anderson Campus
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15232
- UPMC Hillman Cancer Center
-
Quakertown, Pennsylvania, Verenigde Staten, 18951
- Saint Luke's Hospital-Quakertown Campus
-
Sayre, Pennsylvania, Verenigde Staten, 18840
- Guthrie Medical Group PC-Robert Packer Hospital
-
-
South Dakota
-
Aberdeen, South Dakota, Verenigde Staten, 57401
- Avera Cancer Institute-Aberdeen
-
Sioux Falls, South Dakota, Verenigde Staten, 57105
- Avera Cancer Institute
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Vermont
-
Berlin Corners, Vermont, Verenigde Staten, 05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington, Vermont, Verenigde Staten, 05401
- University of Vermont Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Verenigde Staten, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Verenigde Staten, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Aberdeen, Washington, Verenigde Staten, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellingham, Washington, Verenigde Staten, 98225
- PeaceHealth Saint Joseph Medical Center
-
Centralia, Washington, Verenigde Staten, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Verenigde Staten, 98026
- Swedish Cancer Institute-Edmonds
-
Everett, Washington, Verenigde Staten, 98201
- Providence Regional Cancer Partnership
-
Issaquah, Washington, Verenigde Staten, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Verenigde Staten, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Verenigde Staten, 98503
- Providence Regional Cancer System-Lacey
-
Longview, Washington, Verenigde Staten, 98632
- PeaceHealth Saint John Medical Center
-
Port Townsend, Washington, Verenigde Staten, 98368
- Jefferson Healthcare
-
Seattle, Washington, Verenigde Staten, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Verenigde Staten, 98122
- Swedish Medical Center-First Hill
-
Sedro-Woolley, Washington, Verenigde Staten, 98284
- PeaceHealth United General Medical Center
-
Vancouver, Washington, Verenigde Staten, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Verenigde Staten, 99362
- Providence Saint Mary Regional Cancer Center
-
-
Wisconsin
-
Eau Claire, Wisconsin, Verenigde Staten, 54701
- Marshfield Medical Center-EC Cancer Center
-
Marshfield, Wisconsin, Verenigde Staten, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Medical College of Wisconsin
-
Minocqua, Wisconsin, Verenigde Staten, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Verenigde Staten, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Verenigde Staten, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, Verenigde Staten, 54476
- Marshfield Medical Center - Weston
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Patient must be >= 18 years of age
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
-
Patient must have a histologic diagnosis of melanoma belonging to the following American Joint Committee on Cancer (AJCC) 8th edition TNM stages:
- T0, Tx or T1-4; and
- N1b, N2b, N2c, N3b or N3c
-
Patients may have a presentation with primary melanoma with concurrent regional nodal and/or in-transit metastasis; or patients may have a history of primary melanoma or unknown primary melanoma presenting with clinically detected regional nodal and/or in-transit recurrence; and may belong to any of the following groups:
-
Primary cutaneous melanoma with clinically apparent regional lymph node metastases and/or in-transit metastases
-
Clinically detected recurrent melanoma at the proximal regional lymph node(s) basin
-
Primary cutaneous melanoma with concurrent nodal disease involving a single (or multiple) regional nodal group(s) if considered potentially surgically resectable at baseline
-
Clinically detected nodal melanoma (if single site) arising from an unknown primary
-
In-transit cutaneous metastases with or without regional lymph node involvement permitted if considered potentially surgically resectable at baseline
- NOTE: Patients with mucosal and/or uveal melanoma are not eligible for the study
-
-
Patient must be a candidate for definitive surgery and have met with the treating surgical oncologist prior to randomization
-
Patient must not have received any live vaccine within 30 days prior to randomization and while participating in the study. Live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Patients are permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and COVID-19 (Note: intranasal influenza vaccines, such as Flu-Mist [registered trademark] are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily, in order to minimize an overlap of adverse events)
-
Patient must have the presence of injectable and measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, documented by scans obtained within 4 weeks prior to randomization
- NOTE: Injectable disease is defined as an accessible lesion in the skin, subcutaneous tissue or lymph nodes (LN) close to the skin and palpable by physical examination or approachable with ultrasound guidance
-
Absolute neutrophil count (ANC) >= 1,500 /mcL (obtained within 4 weeks prior to randomization)
-
Hemoglobin (Hgb) >= 9 g/dL or >= 5.6 mmol/L (obtained within 4 weeks prior to randomization)
-
Platelets >= 100,000 / mcL (obtained within 4 weeks prior to randomization)
-
Serum creatinine =< 1.5 x institutional upper limit of normal (ULN) or measured or calculated creatinine clearance > 60 mL/min (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl] for patients with creatinine levels > 1.5 x institutional ULN) (obtained within 4 weeks prior to randomization)
-
Serum total bilirubin =< 1.5 x institutional ULN; for total bilirubin level > 1.5 x ULN but =< 3 x ULN, the direct bilirubin must be =< the institutional ULN (obtained within 4 weeks prior to randomization)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (obtained within 4 weeks prior to randomization)
-
International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x institutional ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants (obtained within 4 weeks prior to randomization)
-
Activated partial thromboplastin time (aPTT) =< 1.5 x institutional ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (obtained within 4 weeks prior to randomization)
-
Patients must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A urine or serum pregnancy test must be repeated within 72 hours prior to receiving the first dose of pembrolizumab if the test done for eligibility/randomization is done outside of this 72 hour window. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or abstaining from sexual intercourse from time of randomization, while on study treatment, and continue for 26 weeks after the last dose of protocol treatment
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Patient must not have received prior systemic therapy for melanoma including systemic therapy with an anti-PD-1, anti-PD-L1, anti-CTLA-4, BRAF/MEK inhibitor combination and/or TLR-9 agonist
-
Patient must not have a diagnosis of immunodeficiency or be receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization, except as noted here
- Patients who are currently receiving steroids at a dose of prednisone =< 5 mg daily (or equivalent) are permitted to enroll
- Patients who require topical, ophthalmologic and inhalational steroids are permitted to enroll
- Patients with hypothyroidism who are stable on hormone replacement are permitted to enroll
- Patients who require active immunosuppression with corticosteroids at a dose of prednisone > 5 mg daily (or equivalent) for any reason are ineligible
- Patients with adrenal insufficiency are ineligible
- Patients who have developed autoimmune disorders of grade 4 while on prior immunotherapy are not permitted to enroll on this study. Patients who developed autoimmune disorders of grade =< 3 may enroll if the disorder has resolved to grade =< 1 and the patient has been off systemic corticosteroids at doses > 5 mg for at least 2 weeks prior to randomization
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to randomization are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with a history of brain metastases are not eligible for this study as they do not meet the eligibility staging criteria
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
Patient must not have had an allogeneic tissue/solid organ transplant
-
Patient must not have a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
-
Patient must not have severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients
-
Patient must not have an active infection requiring systemic therapy
-
Patient must not have a known psychiatric or substance abuse disorder that would interfere with the patient's ability to cooperate with the requirements of the study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm A (pembrolizumab)
NEOADJUVANT PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase. ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET/CT throughout the trial and may undergo optional biopsy at baseline and disease progression and optional collection of blood samples throughout the trial. |
Undergo biopsy
Andere namen:
Given IV
Andere namen:
Undergo collection of blood samples
Andere namen:
Undergo CT or PET/CT
Andere namen:
Undergo PET/CT
Andere namen:
Undergo surgery
Andere namen:
|
|
Experimenteel: Arm B (CMP-001, pembrolizumab)
NEOADJUVANT PHASE: Patients receive CMP-001 SC on day 1 of cycle 1 and then intratumorally on days 8 and 15 of cycle 1, days 1, 8, and 15 of cycle 2, and day 1 of cycle 3. Patients also receive pembrolizumab IV over 30 minutes on day 8 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase. ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET/CT throughout the trial and may undergo optional biopsy at baseline and disease progression and optional collection of blood samples throughout the trial. |
Undergo biopsy
Andere namen:
Given IV
Andere namen:
Undergo collection of blood samples
Andere namen:
Undergo CT or PET/CT
Andere namen:
Undergo PET/CT
Andere namen:
Undergo surgery
Andere namen:
Given SC or intratumorally |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pathologic complete response rate
Tijdsspanne: Up to 15 years
|
Will be estimated by the percentage of patients who achieve complete response, partial response or stable disease by Response Evaluation Criteria in Solid Tumors (RECIST) and Immune-Modified RECIST criteria, with exact 90% confidence intervals. |
Up to 15 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overleven zonder terugval
Tijdsspanne: Van randomisatie tot terugval of overlijden (wat zich het eerst voordoet), beoordeeld tot 15 jaar
|
Van randomisatie tot terugval of overlijden (wat zich het eerst voordoet), beoordeeld tot 15 jaar
|
|
|
Algemeen overleven
Tijdsspanne: Van randomisatie tot overlijden door welke oorzaak dan ook, beoordeeld tot 15 jaar
|
Van randomisatie tot overlijden door welke oorzaak dan ook, beoordeeld tot 15 jaar
|
|
|
Radiographic response rate
Tijdsspanne: Up to 15 years
|
Will be assessed using RECIST. |
Up to 15 years
|
|
Incidence of adverse events
Tijdsspanne: Up to 30 days after the last study drug administration
|
Patients will be monitored for adverse events using the National Cancer Institute's Common Terminology Criteria for Adverse Events. |
Up to 30 days after the last study drug administration
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Ahmad Tarhini, ECOG-ACRIN Cancer Research Group
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Neoplasmata per histologisch type
- Huidziektes
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Neuro-endocriene tumoren
- Nevi en melanomen
- Huidneoplasmata
- Huid- en bindweefselaandoeningen
- Melanoma
- Onderzoekstechnieken
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Cytologische technieken
- Cytodiagnose
- Diagnostische technieken, chirurgisch
- Chemie -technieken, analytisch
- Spectrumanalyse
- Biopsie
- Exemplaarbehandeling
- pembrolizumab
- Magnetische resonantiespectroscopie
- Chirurgische procedures, operatief
Andere studie-ID-nummers
- NCI-2020-14174
- U10CA180820 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2020-14174 (Register-ID: CTRP (Clinical Trial Reporting Program))
- EA6194 (Andere identificatie: CTEP)
- EA6194 (Andere identificatie: ECOG-ACRIN Cancer Research Group)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .